Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gynecologic Cancers
•
Ovarian Cancer
How do you approach adjuvant therapy for an early stage ovarian cancer with 75% epithelial and 25% germ cell components?
Related Questions
How have you incorporated mirvetuximab into the treatment of platinum-resistant ovarian cancer?
Given the platinum drug shortage and the recently presented NOW trial, would you consider PARP inhibitor use in place of platinum-based chemotherapy for advanced ovarian cancer?
For a patient with adenosarcoma of the ovary with high grade sarcomatous overgrowth removed intact with appropriate oncologic surgery, is there any role for radiation?
Do you routinely give prophylactic antibiotics/steroids for patients on MEK-inhibitors (e.g., trametinib) to prevent rash/dermatitis?
What are your top takeaways in Gynecologic Cancers from ASCO 2023?
Would you use a PARP inhibitor as treatment for recurrent platinum-sensitive ovarian cancer with a RAD51 (or other moderate-penetration HRD germline) mutation?
Would you hold a PARP inhibitor in the perioperative period for an ileostomy reversal in a patient who has completed primary debulking surgery followed by chemotherapy?
How would you approach adjuvant therapy for a patient who was diagnosed with surgically staged and completely resected stage II high-grade serous ovarian cancer while she prepared for neoadjuvant chemoradiation for rectal cancer?
What factors do you consider when deciding between 3 versus 4 cycles of BEP for ovarian germ cell tumors?
In the absence of a cohesive workflow guiding the use of PARPi in ovarian cancer since the 2022 FDA approval withdrawals, what is your general approach to PARPi usage in the front-line and recurrent setting?
